Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of Bimatoprost SR in open-angle glaucoma or ocular hypertension
2023-504601-36-00Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 21
01
Overview
Phase 3, open-label, single-arm trial of bimatoprost in open-angle glaucoma (OAG) and ocular hypertension, sponsored by AbbVie Inc. Primary endpoints: Long-term safety assessments, Time to first rescue treatment or PRN retreatment and 1 more. Started Nov 2023; status: completed.
02
Drugs
bimatoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2023-504601-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504601-36-00.